Another major breakthrough in treating cancers generally has been the emergence of immune checkpoint inhibitors (ICIs) including antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1). The gene discussed is CTLA4; the disease is cancer.